Methods and products for increasing frataxin levels and uses thereof
AssigneeUniversite Laval
InventorsJACQUES P. TREMBLAY, JOEL ROUSSEAU, PIERRE CHAPDELAINE, ZOE COULOMBE
Life of this patent
Estimating the term…
Abstract
Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of Friedreich ataxia in a subject suffering therefrom.
Claims19
1-20. (canceled)
A method for treating Friedreich ataxia in a subject comprising administering to said subject a transcription activator-like (TAL) effector-based recombinant protein or a nucleic acid encoding said recombinant protein, said recombinant protein comprising:
- i) a TAL effector domain comprising a repeat variable domain (RVD) comprising at least 10 tandem repeat monomers and a half monomer at the C-terminal end of the RVD, each monomer corresponding to an HD, NG, NN, NI, NK or NS module consisting of the amino acid sequence set forth in SEQ ID NO:
- 65 and the half monomer being a truncated monomer consisting of the first 13 contiguous amino acids of SEQ ID NO:
- 65,
- ii) a nuclear localization signal;
- and
- iii) a transcription activation domain,
- wherein said RVD binds to a sequence within nucleotides 5-50 or 81-119 of the frataxin promoter nucleotide sequence set forth in SEQ ID NO:
- 88 of a mammalian frataxin gene comprising at least 75 repeats of GAA trinucleotides in intron 1 thereof, and wherein said recombinant protein increases frataxin expression in said cell.
A method for increasing frataxin expression in a cell comprising a frataxin gene comprising at least 75 repeats of GAA trinucleotides in intron 1 thereof, the method comprising transducing said cell with a transcription activator-like (TAL) effector-based recombinant protein or nucleic acid encoding said recombinant protein, said recombinant protein comprising:
- i) a TAL effector domain comprising a repeat variable domain (RVD) comprising at least 10 tandem repeat monomers and a half monomer at the C-terminal end of the RVD, each monomer corresponding to an HD, NG, NN, NI, NK or NS module consisting of the amino acid sequence set forth in SEQ ID NO:
- 65 and the half monomer being a truncated monomer consisting of the first 13 contiguous amino acids of SEQ ID NO:
- 65,
- ii) a nuclear localization signal;
- and
- iii) a transcription activation domain,
- wherein said RVD binds to a sequence within nucleotides 5-50 or 81-119 of the frataxin promoter nucleotide sequence set forth in SEQ ID NO:
- 88 of a mammalian frataxin gene in said cell, thereby increasing frataxin expression in said cell.
Dependencies are inferred from the claim text.